What are Spravato's marketing services?
Spravato (esketamine nasal spray) is marketed for treatment-resistant depression (TRD) and depressive symptoms in adults with Major Depressive Disorder (MDD) with acute suicidal ideation or behavior [1]. Janssen, a pharmaceutical company, is responsible for Spravato's marketing and distribution [2]. The marketing efforts focus on educating healthcare providers about the drug's availability, appropriate patient selection, and administration protocols [3].
Who is Spravato marketed to?
Spravato is primarily marketed to healthcare providers, including psychiatrists and other mental health professionals who treat adults with TRD and MDD with acute suicidal ideation or behavior [1][3]. The marketing also targets these professionals regarding the required in-office administration and monitoring due to the drug's potential for sedation and dissociation [4].
How is Spravato administered and monitored?
Spravato is administered in a certified healthcare setting under the supervision of a healthcare provider [4]. Patients must be monitored for at least two hours after administration due to potential side effects like sedation and dissociation [4]. This mandated administration and monitoring protocol is a significant aspect of Spravato's distribution and marketing, influencing how it is prescribed and accessed [3][4].
What is the availability of Spravato?
Spravato is available through a Risk Evaluation and Mitigation Strategy (REMS) program, which requires administration in certified healthcare settings [4]. Patients can only receive Spravato under the supervision of a healthcare provider at these certified facilities [4].
What are the risks associated with Spravato?
Spravato carries risks including sedation, dissociation, abuse and misuse, and the potential for bladder adverse events [4]. Patients are monitored for these risks during and after administration [4].
What are the indications for Spravato?
Spravato is indicated for treating depressive symptoms in adults with Major Depressive Disorder (MDD) who have acute suicidal ideation or behavior [1]. It is also used for treatment-resistant depression (TRD) in adults [1].
What is the scientific rationale behind Spravato?
Spravato is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which is thought to contribute to its rapid antidepressant effects [5]. This mechanism differs from traditional antidepressants, which primarily target monoamine systems [5].
What are the regulatory requirements for Spravato?
Due to its potential for abuse and misuse, Spravato is subject to a REMS program [4]. This program mandates that the drug be administered in a certified healthcare setting and requires healthcare providers to monitor patients for at least two hours post-administration [4].
What is the patent status of Spravato?
Information on Spravato's patent status can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patent filings and expirations. Patents for drugs are crucial for determining market exclusivity and the potential for generic competition [6].
Sources:
[1] https://www.spravato.com/
[2] https://www.janssen.com/
[3] https://www.prnewswire.com/news-releases/spravato-esketamine-c-iii-nasal-spray-is-now-available-for-the-treatment-of-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-300806322.html
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210515s016,210516s017lbl.pdf
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578139/
[6] https://drugpatentwatch.com/